SOX1 Functions as a Tumor Suppressor by Repressing HES1 in Lung Cancer

• Published in: Cancers Vol. 15; no. 8; p. 2207
• Main Authors: Chang, Shan-Yueh, Wu, Ti-Hui, Shih, Yu-Lueng, Chen, Ying-Chieh, Su, Her-Young, Chian, Chih-Feng, Lin, Ya-Wen
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 08.04.2023; MDPI
• Subjects: Biobanks; Bioinformatics; Cancer therapies; Carcinogenesis; Cell fate; Cell proliferation; Cervical cancer; Chromatin; Development and progression; DNA methylation; Doxycycline; Drug resistance; Embryogenesis; Enhancer-of-split protein; Epigenetics; Gene expression; Genetic aspects; Genomes; Health aspects; Immunoprecipitation; Immunotherapy; Lung cancer; Metastases; Metastasis; Mutation; Non-small cell lung carcinoma; Phenotypes; Polymerase chain reaction; Prognosis; Reverse transcription; Small cell lung carcinoma; Software; Transcription factors; Tumor suppressor genes; Tumors; Taiwan; United States > US; lung cancer; tumor suppressor; HES1; SOX1
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15082207

The development of lung cancer is a complex process that involves many genetic and epigenetic changes. Sex-determining region Y (SRY)-box (SOX) genes encode a family of proteins that are involved in the regulation of embryonic development and cell fate determination. SOX1 is hypermethylated in human cancers. However, the role of SOX1 in the development of lung cancer is unclear. We used quantitative methylation-specific polymerase chain reaction (MSP), quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis, and web tools to confirm the frequent epigenetic silencing of SOX1 in lung cancer. Stable overexpression of SOX1 repressed cell proliferation, anchorage-independent growth, and invasion in vitro as well as cancer growth and metastasis in a xenograft mouse model. Knockdown of SOX1 by the withdrawal of doxycycline partly restored the malignant phenotype of inducible SOX1-expressing NSCLC cells. Next, we discovered the potential downstream pathways of SOX1 using RNA-seq analysis and identified HES1 as a direct target of SOX1 using chromatin immunoprecipitation (ChIP)-PCR. Furthermore, we performed phenotypic rescue experiments to prove that overexpression of HES1-FLAG in SOX1-expressing H1299 cells partly reversed the tumor-suppressive effect. Taken together, these data demonstrated that SOX1 acts as a tumor suppressor by directly inhibiting HES1 during the development of NSCLC.